{"result": "(\"entity\"<|>NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY<|>ORGANIZATION<|>The North American Neuroendocrine Tumor Society (NANETS) is an organization that provides guidelines for the diagnosis and management of neuroendocrine tumors, including pheochromocytoma, paraganglioma, and medullary thyroid cancer.)\n##\n(\"entity\"<|>MEDULLARY THYROID CANCER<|>EVENT<|>Medullary thyroid cancer is a type of thyroid cancer that can occur sporadically or as part of a genetic syndrome, often associated with mutations in the RET proto-oncogene.)\n##\n(\"entity\"<|>MEN2A<|>EVENT<|>Multiple Endocrine Neoplasia type 2A (MEN2A) is a genetic syndrome that can lead to medullary thyroid cancer and pheochromocytoma.)\n##\n(\"entity\"<|>MEN2B<|>EVENT<|>Multiple Endocrine Neoplasia type 2B (MEN2B) is a genetic syndrome associated with a higher risk of medullary thyroid cancer and other endocrine tumors.)\n##\n(\"entity\"<|>FEOCROMOCITOMA<|>EVENT<|>Pheochromocytoma is a tumor of the adrenal gland that can occur in conjunction with medullary thyroid cancer, particularly in patients with MEN2A.)\n##\n(\"entity\"<|>CALCITONIN<|>PERSON<|>Calcitonin is a hormone produced by the thyroid gland that is used as a marker for medullary thyroid cancer and can help predict the extent of the disease.)\n##\n(\"entity\"<|>I-131<|>EVENT<|>I-131 is a radioactive isotope used in the treatment of thyroid cancer, particularly differentiated thyroid cancer.)\n##\n(\"relationship\"<|>NORTH AMERICAN NEUROENDOCRINE TUMOR SOCIETY<|>MEDULLARY THYROID CANCER<|>NANETS provides guidelines for the diagnosis and management of medullary thyroid cancer<|>8)\n##\n(\"relationship\"<|>MEDULLARY THYROID CANCER<|>MEN2A<|>Medullary thyroid cancer can be a manifestation of MEN2A syndrome<|>7)\n##\n(\"relationship\"<|>MEDULLARY THYROID CANCER<|>MEN2B<|>Medullary thyroid cancer can be a manifestation of MEN2B syndrome<|>7)\n##\n(\"relationship\"<|>MEN2A<|>FEOCROMOCITOMA<|>MEN2A is associated with an increased risk of pheochromocytoma<|>6)\n##\n(\"relationship\"<|>MEN2B<|>FEOCROMOCITOMA<|>MEN2B is associated with an increased risk of pheochromocytoma<|>6)\n##\n(\"relationship\"<|>MEDULLARY THYROID CANCER<|>CALCITONIN<|>Calcitonin levels are used to predict the extent of medullary thyroid cancer<|>8)\n##\n(\"relationship\"<|>MEDULLARY THYROID CANCER<|>I-131<|>I-131 is used in the treatment of differentiated thyroid cancer, which can include cases of medullary thyroid cancer<|>5)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: Force on Medullary Thyroid Carcinoma. Thyroid.\n       2015;25(6):567-610.\n\n\n\n180                                                                                                                                                                                                                                                                                          181\n---\n                                                                                                                                                                                                                                           TIROIDES  3\n\n\n\n     COMENTARIO                                                                                                                              44  En relación con la utilización de la PET con 18F-FDG en los carcinomas\n     Los carcinomas medulares de tiroides se pueden presentar de forma esporádica o como                                                         diferenciados de tiroides, indique cuál de las siguientes afirmaciones es cierta:\n     resultado de una mutación activante del protooncogen RET en línea germinal. Aunque la                                                       A. La PET 18F-FDG tiene gran valor en la estadificación inicial de estos tumores.\n     frecuencia respectiva depende de la serie consultada, en todas ellas son más frecuentes los                                                 B. Una alta captación de FDG por parte de las metástasis de estos tumores predice una\n     casos esporádicos, que suponen al menos un 75% de los casos (opción A falsa).                                                                   mala respuesta al tratamiento con I-131.\n     Aproximadamente el 95% de los pacientes con MEN2B tienen mutaciones en línea germinal                                                       C. La PET 18F-FDG debería ser utilizada en el seguimiento de la mayoría de estos tumores.\n     en el exón 16 (codón M918T) del oncogen RET. En cambio, la mutación del codón 634 da                                                        D.  La sensibilidad de la PET18F-FDG para detectar posibles metástasis de estos tumores\n     origen a MEN2A (opción B falsa).                                                                                                                no se modifica con el estímulo con TSH.\n     El diagnóstico de feocromocitoma es concurrente con el de MEN2A en el 35% al 73% de\n     los casos, y es la primera manifestación del síndrome en el 9% al 27% de los casos. En la\n     Guía de carcinoma medular de la ATA 2015 se indica que los feocromocitomas se suelen                                                        COMENTARIO\n     diagnosticar en la tercera o cuarta década de la vida coincidiendo o siguiendo al diagnós-                                                  En la guía de la ATA de manejo del cáncer diferenciado de tiroides se establece una se-\n     tico del carcinoma medular. Dada su posible presencia en el momento del diagnóstico de                                                      rie de recomendaciones para la utilización de la PET 18F-FDG en el seguimiento del cán-\n     carcinoma medular, se recomienda su cribado antes de cualquier procedimiento quirúrgi-                                                      cer de tiroides. Establece que debe considerarse su utilización en caso de pacientes con\n     co. Igualmente se recomienda iniciar cribado de feocromocitoma a edades tan tempranas                                                       alto riesgo de recidiva con niveles de tiroglobulina (TG) elevados (en general > 10 ng/ml)\n     como los 11 y 16 años, según la mutación causante del MEN. Por lo tanto, aunque es cierto                                                   con rastreos con I-131 negativos.\n     que lo habitual es que se diagnostique después de que se haya diagnosticado el carcinoma                                                    Igualmente se indica que se puede considerar la utilización de la PET 18F-FDG en:\n     medular, existen excepciones.\n     Los niveles preoperatorios de calcitonina son útiles para predecir la extensión de la enfer-                                                1.  Como parte inicial de la estadificación en tumores pobremente diferenciados o carcino-\n     medad en este momento y para planificar la intervención quirúrgica. En efecto, niveles de                                                       mas invasivos de células de Hürthle.\n     calcitonina superiores a 20, 50, 200 y 500 pg/ml se asocian respectivamente con metásta-                                                    2.  Como herramienta pronóstica en pacientes con enfermedad metastásica para identifi-\n     sis ganglionares del compartimento central y lateral ipsilateral, del compartimento central                                                     car lesiones de alto riesgo de rápida progresión.\n     contralateral, del compartimento lateral contralateral y con metástasis a distancia. En cam-                                                3.  Para evaluar la respuesta al tratamiento sistémico o local de enfermedad metastásica o\n     bio, valores inferiores a 10 pg/ml predicen una supervivencia a 10 años de un 97,7%.                                                            localmente invasiva.\n     Referencias:                                                                                                                                Así pues, tanto la opción A como la C son falsas.\n     • Chen H, Sippel RS, O’Dorisio MS, Vinik AI, Lloyd RV, Pacak K; North American Neuroendocrine Tumor Society (NANETS). The North\n       American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors:                      Sin embargo, la opción B es verdadera. En efecto, la captación en una PET 18F-FDG en pa-\n       pheochromocytoma, paraganglioma, and medullary thyroid cancer. Pancreas. 2010;39:775-83.                                                  cientes con carcinoma diferenciado de tiroides metastásico es\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}